Merck Patent Gmbh

Viventia Bio Inc.

Viventia Biotech Inc.

Francis J. Carr

Koen Hellendoorn

Nicholas Ronald Glover

Jeannick Cizeau

Joycelyn Entwistle

Glen Christopher Macdonald

Denis Georges Bosc

Matthew Baker

Francis Joseph Carr

Francis J Carr

Glen MacDonald

Francina C Chahal

The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.

Cytotoxins comprising modified bouganin toxin for the treatment of cancer

Modified bouganin proteins, cytotoxins and methods and uses thereof

Growing community of inventors

CA

Denis Georges Bosc